循環腫瘤細胞在非小細胞肺癌中的臨床價值_《華西醫學》

作者：

楊麗菲 ^1,2 ,  周麟 ¹

關鍵詞：

循環腫瘤細胞肺癌診斷療效評估預后

DOI：

10.7507/1002-0179.20130462

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目前，肺癌已成為癌癥患者第一殺手，其每年以3%的速度增長且5年總體生存率僅為20%～25%。初治及復發肺癌的早期診斷、治療效果的快速評價仍是一個難題。近幾年來，越來越多的學者開始關注循環腫瘤細胞（CTC）。CTC的相關研究表明：其檢測對體外肺癌的早期診斷、化學療法藥物效果的快速評估、肺癌的復發檢測等有幫助。現對CTC在非小細胞肺癌診斷、治療及預后方面的研究進展問題作一綜述。

引用本文： 楊麗菲,周麟. 循環腫瘤細胞在非小細胞肺癌中的臨床價值. 華西醫學, 2013, 28(9): 1476-1479. doi: 10.7507/1002-0179.20130462 復制

1.	Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood[J]. Proc Natl Acad Sci USA, 2000, 97(26): 14608-14613.
2.	Hunter K. Host genetics influence tumor metastasis[J]. Nat Rev Cancer, 2006, 6(2): 141-146.
3.	Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Aust Med J, 1896, 14: 146-149.
4.	Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cance J Clin, 2006, 56(2): 106-130.
5.	National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409.
6.	Smit AA, Moons-Pasic A. Is lung cancer screening using CT a good idea?[J]. Ned Tijdschr Geneeskd, 2011, 155(50): 3960.
7.	Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer[J]. Clin Cancer Res, 2009, 15(22): 6980-6986.
8.	Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients[J]. J Thorac Oncol, 2009, 4(1): 30-36.
9.	Wendel M, Bazhenova L, Boshuizen R, et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology[J]. Phys Biol, 2012, 9(1): 016005.
10.	Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected[J]. J Clin Oncol, 2011, 29(12): 1508-1511.
11.	Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
12.	Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials[J]. Clin Lung Cancer, 2012, 13(2): 107-114.
13.	Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib[J]. N Engl J Med, 2005, 352(8): 786-792.
14.	Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J]. Proc Natl Acad Sci USA, 2005, 102(21): 7665-7670.
15.	Engelman JA, Zejnullahu K, Mitsudomi T, et al. Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316(5827): 1039-1043.
16.	Bean J, Brennan C, Jy S, et al. Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proc Natl Acad Sci USA, 2007, 104(52): 20932-20937.
17.	Maheswaran S, Sequist L, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells[J]. N Engl J Med, 2008, 359(4): 366-377.
18.	Lecharpentier A, Vielh P, Perez-Moreno P, et al. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer[J]. Br J Cancer, 2011, 105(9): 1338-1341.
19.	Hou M, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer[J]. Am J Pathol, 2011, 178(3): 989-996.
20.	Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells[J]. PLoS One, 2010, 5(9): 12517.
21.	Ksi??kiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells[J]. Pathobiology, 2012, 79(4): 195-208.
22.	Fisher D, Orazio A. PhaseⅡ andⅢ trials comparison of four chemotherapy regimens in advanced non-small-cell lung cancer (ECOG 1594)[J]. Clin Lung Cancer, 2000, 2(1): 21-22.
23.	D’Amato TA, Landreneau RJ, McKenna RJ, et al. Prevalence of in vitro extreme chemotherapy resistance in resected non-small-cell lung cancer[J]. Ann Thorac Surg, 2006, 81(2): 440-446.
24.	Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(12): 1556-1563.
25.	Ge J, Shi D, Wu C, et al. Fluctuation of circulating tumor cells approach before in patients with lung cancer by real-time fluorescent quantitative-PCR and after radiotherapy[J]. J Cancer Res Ther, 2005, 1(4): 221-226.
26.	Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phaseⅡ clinical trial of pertuzumab and erlotinib[J]. Clin Cancer Res, 2012, 18(8): 2391-2401.
27.	Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the cell search Assay? and the isolation by size of epithelial tumor cell method[J]. Int J Cancer, 2011, 129(7): 1651-1660.
28.	Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res, 2011, 17(4): 827-835.

1. 　Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood[J]. Proc Natl Acad Sci USA, 2000, 97(26): 14608-14613.
2. 　Hunter K. Host genetics influence tumor metastasis[J]. Nat Rev Cancer, 2006, 6(2): 141-146.
3. 　Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Aust Med J, 1896, 14: 146-149.
4. 　Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cance J Clin, 2006, 56(2): 106-130.
5. 　National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409.
6. 　Smit AA, Moons-Pasic A. Is lung cancer screening using CT a good idea?[J]. Ned Tijdschr Geneeskd, 2011, 155(50): 3960.
7. 　Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer[J]. Clin Cancer Res, 2009, 15(22): 6980-6986.
8. 　Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients[J]. J Thorac Oncol, 2009, 4(1): 30-36.
9. 　Wendel M, Bazhenova L, Boshuizen R, et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology[J]. Phys Biol, 2012, 9(1): 016005.
10. 　Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected[J]. J Clin Oncol, 2011, 29(12): 1508-1511.
11. 　Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
12. 　Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials[J]. Clin Lung Cancer, 2012, 13(2): 107-114.
13. 　Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib[J]. N Engl J Med, 2005, 352(8): 786-792.
14. 　Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J]. Proc Natl Acad Sci USA, 2005, 102(21): 7665-7670.
15. 　Engelman JA, Zejnullahu K, Mitsudomi T, et al. Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316(5827): 1039-1043.
16. 　Bean J, Brennan C, Jy S, et al. Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proc Natl Acad Sci USA, 2007, 104(52): 20932-20937.
17. 　Maheswaran S, Sequist L, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells[J]. N Engl J Med, 2008, 359(4): 366-377.
18. 　Lecharpentier A, Vielh P, Perez-Moreno P, et al. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer[J]. Br J Cancer, 2011, 105(9): 1338-1341.
19. 　Hou M, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer[J]. Am J Pathol, 2011, 178(3): 989-996.
20. 　Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells[J]. PLoS One, 2010, 5(9): 12517.
21. 　Ksi??kiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells[J]. Pathobiology, 2012, 79(4): 195-208.
22. 　Fisher D, Orazio A. PhaseⅡ andⅢ trials comparison of four chemotherapy regimens in advanced non-small-cell lung cancer (ECOG 1594)[J]. Clin Lung Cancer, 2000, 2(1): 21-22.
23. 　D’Amato TA, Landreneau RJ, McKenna RJ, et al. Prevalence of in vitro extreme chemotherapy resistance in resected non-small-cell lung cancer[J]. Ann Thorac Surg, 2006, 81(2): 440-446.
24. 　Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(12): 1556-1563.
25. 　Ge J, Shi D, Wu C, et al. Fluctuation of circulating tumor cells approach before in patients with lung cancer by real-time fluorescent quantitative-PCR and after radiotherapy[J]. J Cancer Res Ther, 2005, 1(4): 221-226.
26. 　Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phaseⅡ clinical trial of pertuzumab and erlotinib[J]. Clin Cancer Res, 2012, 18(8): 2391-2401.
27. 　Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the cell search Assay? and the isolation by size of epithelial tumor cell method[J]. Int J Cancer, 2011, 129(7): 1651-1660.
28. 　Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res, 2011, 17(4): 827-835.

上一篇
吲哚胺2，3-雙加氧酶與腦腫瘤免疫耐受機制的研究進展
下一篇
大腦膠質瘤病一例

《華西醫學》

循環腫瘤細胞在非小細胞肺癌中的臨床價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

循環腫瘤細胞在非小細胞肺癌中的臨床價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料